• First physician participant enrolled in the ColoSTAT® Access Program
• Establishes a controlled pathway for the safe and effective introduction of ColoSTAT® into routine clinical use
• Creates a platform for clinician adoption, operational readiness and commercial scale-up

Rhythm Biosciences Ltd (ASX:RHY), a predictive cancer diagnostics technology company, has announced the enrolment of the first physician participant in its ColoSTAT® Access Program (Access Program), a key commercial milestone in the Company's transition of ColoSTAT® from clinical development to routine clinical use and revenue-generating clinical deployment. The Access Program has been established as Rhythm's initial commercial deployment framework for ColoSTAT®, enabling eligible clinicians to begin offering the test to appropriate patients while the Company finalises broader market access pathways and establishes repeat ordering behaviour under standard commercial pricing. Under the terms of the Access Program, participating clinicians receive an initial allocation of ColoSTAT® tests at no cost to allow a routine test ordering and delivery process to be established. Once the Company and participant are confident that patient safety and clinical efficacy is assured, further tests will be supplied on standard commercial terms. The enrolment of the first Access Program participant represents an important step toward demonstrating that ColoSTAT® is ready for real-world use and provides early validation of clinician engagement and potential demand for a more accessible blood-based testing option. This milestone further transitions the Company's profile from a research and product development organisation to a commercial business, establishing a foundation upon which future market access, partnership and distribution strategies can be built and establishing a pathway to recurring test revenue.

Rhythm Biosciences will focus on expanding clinician participation in the Access Program, generating real-world clinical and operational data, progressing discussions with potential commercial partners and distributors, and continuing preparation for broader market entry.